Want to join the conversation?
Global pharmaceutical giant $ABBV today got the approval of VIEKIRAX from Japanese Ministry of Health, Labour and Welfare for the treatment of adult patients with HCV-1 infection, including those with compensated liver cirrhosis. With this approval, $ABBV is going to address the unmet need of approx. 2MM HCV patients in Japan.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.